Alumis (NASDAQ:ALMS) Stock Price Expected to Rise, Guggenheim Analyst Says

Alumis (NASDAQ:ALMS) had its price objective upped by stock analysts at Guggenheim from $18.00 to $32.00 in a report issued on Wednesday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s target price indicates a potential upside of 76.02% from the stock’s current price.

Several other equities research analysts have also recently commented on ALMS. Leerink Partners lifted their price target on shares of Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wall Street Zen raised shares of Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Wells Fargo & Company upped their target price on shares of Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday. HC Wainwright increased their price target on Alumis from $14.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Alumis in a research note on Tuesday. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.33.

Alumis Stock Performance

NASDAQ ALMS opened at $18.18 on Wednesday. The stock has a market capitalization of $1.90 billion, a P/E ratio of -4.49 and a beta of -2.09. Alumis has a 52 week low of $2.76 and a 52 week high of $22.30. The stock has a fifty day moving average of $8.92 and a 200-day moving average of $5.80.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million during the quarter, compared to analyst estimates of $3.14 million. Equities research analysts forecast that Alumis will post -8.51 earnings per share for the current fiscal year.

Insider Activity at Alumis

In other Alumis news, Director Srinivas Akkaraju purchased 186,377 shares of the stock in a transaction on Friday, December 5th. The stock was bought at an average cost of $9.84 per share, for a total transaction of $1,833,949.68. Following the completion of the acquisition, the director directly owned 1,265,253 shares of the company’s stock, valued at $12,450,089.52. The trade was a 17.28% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James B. Tananbaum purchased 190,500 shares of the company’s stock in a transaction dated Wednesday, November 19th. The shares were acquired at an average cost of $6.56 per share, for a total transaction of $1,249,680.00. Following the transaction, the director owned 2,542,003 shares of the company’s stock, valued at $16,675,539.68. This trade represents a 8.10% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 2,788,875 shares of company stock worth $18,352,357 in the last quarter. Corporate insiders own 40.70% of the company’s stock.

Hedge Funds Weigh In On Alumis

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after buying an additional 4,926 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Alumis by 24.0% during the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock worth $378,000 after acquiring an additional 11,949 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Alumis during the first quarter worth $111,000. Rhumbline Advisers lifted its position in Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after acquiring an additional 2,949 shares in the last quarter. Finally, Kera Capital Partners Inc. acquired a new position in Alumis in the 2nd quarter worth $32,000.

More Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Envudeucitinib met all primary and key secondary endpoints in two Phase III plaque psoriasis studies, driving strong efficacy headlines and a roughly 95% intraday share reaction as investors price in commercial potential. ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
• Positive Sentiment: Multiple analysts bumped targets and issued buy/overweight ratings after the clinical readouts (examples include Guggenheim, Morgan Stanley, Wells Fargo), lifting consensus upside and momentum. Higher price targets support further upside expectations. What’s Going On With Alumis Stock Thursday?
• Neutral Sentiment: Alumis priced an upsized underwritten offering of 17.65 million shares at $17.00 per share (approx. $300M gross proceeds) and granted a 30‑day option to buy an additional 2.6475 million shares; the deal is expected to close around Jan. 9, 2026. This is a financing to advance the pipeline but is a material capital raise. Alumis Announces Pricing of Upsized Public Offering of Common Stock
• Negative Sentiment: The offering is entirely new shares sold by the company, meaning significant dilution for existing shareholders; issuing 17.65M shares (plus option) can weigh on near-term per‑share metrics and valuation. Alumis Inc. Announces Pricing of Upsized Public Offering
• Negative Sentiment: Heavy trading and rapid price gains increase short-term volatility risk; some investors may take profits after the clinical-driven rally while others reassess post-offering share count and forward guidance. Alumis up 95% on envudeucitinib results in psoriasis

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.